Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Repinatrabit Co-administered With Various Drugs in Healthy Participants
NCT07446400Phase 1Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of repinatrabit in gout (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Observable Concentration at Time t and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
repinatrabit
03
Conditions
gout
Beyond the preview
Go deeper on NCT07446400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446400.